Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD

Introduction: In pivotal trials of patients with autosomal dominant polycystic kidney disease at risk of rapid progression, tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in early-to-moderate (TEMPO 3:4 [NCT00428948]) and moderate- to late-stage (REPRISE [NCT02160145]) chronic...

Full description

Bibliographic Details
Main Authors: Andrew J. Mallett, Ronald D. Perrone, Gopala Rangan, Carmel Hawley, Ragada El-Damanawi, Thomas F. Hiemstra, Carolina Townsend Arellano, Jennifer Lee, Vicente E. Torres
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Kidney International Reports
Subjects:
autosomal dominant polycystic kidney disease
clinical trial
chronic kidney disease
persistence
tolvaptan
treatment effect
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024921000164

Internet

http://www.sciencedirect.com/science/article/pii/S2468024921000164

Similar Items